MEDI 8852

Drug Profile

MEDI 8852

Alternative Names: MEDI8852

Latest Information Update: 04 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Humabs BioMed
  • Developer MedImmune
  • Class Antivirals; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Influenza A virus infections

Most Recent Events

  • 27 Oct 2017 Efficacy and adverse events data from a phase Ib/IIa trial in Influenza-A virus infections presented at the Infectious Disease Week-2017 (IDW-20107)
  • 05 Apr 2017 MedImmune withdraws a phase II trial prior to enrollment due to company decision in Influenza-A virus infections (Combination therapy) in Sweden, Spain, Denmark, Latvia, Germany and Czech Republic (IV) (NCT03028909)
  • 01 Dec 2016 MedImmune completes a phase I/II trial in Influenza-A virus infections (Monotherapy, Combination therapy) in USA and South Africa (IV) (NCT02603952)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top